(CercleFinance.com) – AstraZeneca loses just under 1% in London, penalized by an analysis by UBS which lowers its recommendation on the stock from ‘buy’ to ‘neutral’ while lowering its price target to 10100 pence (against 10,500 pence previously).
The analyst believes it’s time to hit the pause button. “With no catalysts for the rest of the year and with some risk of negative earnings momentum, it’s time for a breather,” UBS said.
Nevertheless, AstraZeneca announced last week that phase III results published in The Lancet Respiratory Medicine had shown that AstraZeneca’s Evusheld (tixagevimab and cilgavimab) offered ‘clinically and statistically significant’ protection as an outpatient treatment for Mild to moderate Covid and against disease progression to severe forms or death, compared to placebo.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
